Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Schizophrenia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Schizophrenia
    Schizophrenia and Bipolar Disorder Share Genetic Roots, Researchers Find - (DGNews)
    Long-Acting Risperidone Shows Benefits in Recent-Onset Schizophrenia: Presented at WCBP - (DGDispatch)
    Injectable Risperidone Superior to Oral Quetiapine in Stable Patients With Schizophrenia Who Need Treatment Switch: Presented at WCBP - (DGDispatch)
    TopAbstracts in Schizophrenia 06/25/2009 - (DGNews)
    TopAbstracts in Schizophrenia 06/11/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Schizophrenia
    • Major Depression and Psychoses: Screening, Accurately Diagnosing, and Properly Managing in Primary Care
    • Consistent Approach and Assessment Tools Aid Screening for Major Depressive Disorder and Psychosis in Primary Care
    • Navigating Differential Diagnosis in Major Depressive Disorder: The Role of the Primary Care Physician
    • Newer Classes Enhance Traditional Antidepressants and Are Preferred First-Line Therapies in Primary Care
    • Optimizing the Management of Schizophrenia: Evidence-Based Methods to Minimize the Burden of Disease in Managed Care

      Webcasts/CME archive

       Recent cases - Schizophrenia
        Localisation Using Mini C-Arm Fluoroscopy of Needles Ingested by a Woman with Schizophrenia: A Case Report
        Schizophrenia Spectrum Disorders in a Nigerian Family: 4 Case Reports
        Massive Pulmonary Emboli Associated with Olanzapine
        Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
        Diabetic Control and Atypical Antipsychotics: A Case Report

        Cases archive
          




        my personal edition > schizophrenia > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Second-Generation Antipsychotics Are No Better Than First-Generation Drugs for Schizophrenia

        LONDON -- March 27, 2008 -- Second-generation antipsychotic drugs are not necessarily better than the first-generation drug haloperidol at treating a first episode of schizophrenia. This is the conclusion of authors of an article published in this week's issue of The Lancet.

        Second-generation drugs, introduced over a decade ago, are purported to be more effective and less likely to induce motor side effects, such as stiffness and tremors, than first-generation drugs. However, results from studies comparing the 2 types of drugs have not been reliable -- studies have over-represented men and under-represented those with other issues such as drug abuse. Moreover, these trials were often too short. The question of which drugs are more effective is an important one, as many of the newer drugs are more expensive.

        Rene Kahn, MD, PhD, University Medical Centre, Utrecht, Netherlands, and colleagues conducted an open, randomised trial in 14 countries (13 European countries and Israel), which included 498 patients aged 18 to 40 years. The participants were randomly assigned to 1 low-dose first-generation drug (haloperidol) (n = 103) or to 1 of 4 higher-dose second-generation drugs (amisulpride [n = 104], olanzapine [n = 105], quetiapine [n = 104], or ziprasidone [n = 82]).

        Over the following 12 months, more patients discontinued treatment in the haloperidol group (63 individuals), than in the others: amisulpride (32), olanzapine (30), quetiapine (51), and ziprasidone (31). However, the reductions in all symptoms were about the same for all groups, at around 60% -- what the authors described as "a clinically meaningful response." When the authors further analysed the data according to gender, tendencies towards suicide, and substance abuse, they found no significant differences among the drugs.

        The authors concluded, "Although the high continuation rates for several of the second-generation antipsychotic drugs suggest that clinically meaningful long-term antipsychotic treatment is achievable in the first episode of schizophrenia, it cannot be concluded that second-generation antipsychotic drugs are more efficacious than haloperidol in the treatment of these patients."

        In an accompanying commentary, Robert A. Rosenheck, MD, Department of Veterans Affairs Connecticut Health Care System, Bedford, Massachusetts, said, "Whether use of atypical antipsychotics in either chronic or first-episode schizophrenia should be limited to situations in which they are specifically indicated (eg, in the presence of tardive dyskinesia, akathesia, or pseudoparkinsonism) is a question that must now be faced head-on. Addressing this question poses a major challenge to both cost-effectiveness assessment and to mental health policy making."

        SOURCE: The Lancet



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send